{"id":206,"date":"2020-12-21T06:29:28","date_gmt":"2020-12-21T06:29:28","guid":{"rendered":"http:\/\/goldenspace.ir\/media\/?p=206"},"modified":"2020-12-21T06:29:28","modified_gmt":"2020-12-21T06:29:28","slug":"company-of-the-year-abbott","status":"publish","type":"post","link":"https:\/\/mediakavosh.com\/fa\/company-of-the-year-abbott\/","title":{"rendered":"Company of the Year: Abbott"},"content":{"rendered":"
\n

Four years ago Abbott sought to\u00a0get out of\u00a0<\/a>its acquisition of point-of-care diagnostics manufacturer Alere amid billing concerns and a recall.\u00a0The deal ultimately went through in 2017 for $5.3 billion as one of the last big M&A plays under CEO of 21 years Miles White.<\/p>\n

Fast forward a few years and massive demand for coronavirus testing prompted Abbott to, in a matter of months, more than double the U.S. footprint of the portable diagnostic machines descendent from Alere and typically used to test for infections like strep and flu in doctor’s offices.<\/p>\n

Speaking to investors in October, newly minted CEO Robert Ford called the recent testing expansion “the execution of that Alere strategy, which is to build a whole new testing platform outside of the walls of a lab,” adding, “COVID has actually given us an opportunity to accelerate that strategy.”<\/p>\n

Andrea Wainer, head of rapid and molecular diagnostics, said that by March of this year there was “no turning back” for Abbott’s team in shifting resources to coronavirus response, and echoed Ford’s sentiment, noting that previous\u00a0<\/strong>“inertia” against point-of-care testing by those accustomed to more traditional settings has given way during the pandemic.<\/p>\n

The Chicago-area company’s ability to develop, manufacture and scale molecular, antigen and antibody tests \u2014 which resulted in $881 million in related revenues in the third quarter alone \u2014 has made it a critical player in the U.S. effort to track the virus’ spread.<\/p>\n

\n

Timeline of Abbott’s coronavirus test rollout<\/h4>\n